Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ROIV

ROIV - Roivant Sciences Ltd. Stock Price, Fair Value and News

10.95USD-0.34 (-3.01%)Market Closed

Market Summary

ROIV
USD10.95-0.34
Market Closed
-3.01%

ROIV Stock Price

View Fullscreen

ROIV RSI Chart

ROIV Valuation

Market Cap

9.1B

Price/Earnings (Trailing)

2.06

Price/Sales (Trailing)

73.82

EV/EBITDA

0.65

Price/Free Cashflow

-10.85

ROIV Price/Sales (Trailing)

ROIV Profitability

EBT Margin

3461.24%

Return on Equity

72.69%

Return on Assets

60.54%

Free Cashflow Yield

-9.22%

ROIV Fundamentals

ROIV Revenue

Revenue (TTM)

123.2M

Rev. Growth (Yr)

62.63%

Rev. Growth (Qtr)

0.11%

ROIV Earnings

Earnings (TTM)

4.4B

Earnings Growth (Yr)

1.5K%

Earnings Growth (Qtr)

1.6K%

Breaking Down ROIV Revenue

Last 7 days

-1.8%

Last 30 days

6.5%

Last 90 days

-0.6%

Trailing 12 Months

20.2%

How does ROIV drawdown profile look like?

ROIV Financial Health

Current Ratio

27.79

Debt/Equity

0.07

Debt/Cashflow

-2.07

ROIV Investor Care

Shares Dilution (1Y)

6.25%

Diluted EPS (TTM)

5.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202361.3M81.9M102.6M123.2M
202255.3M328.0M600.7M873.4M
202123.8M30.0M42.6M61.2M
202067.7M56.7M45.7M34.8M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Roivant Sciences Ltd.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 20, 2024
venker eric
sold (taxes)
-181,954
11.37
-16,003
president & coo
May 20, 2024
gline matthew
sold (taxes)
-124,445
11.37
-10,945
ceo
May 20, 2024
kumar rakhi
sold (taxes)
-15,497
11.37
-1,363
chief accounting officer
Apr 28, 2024
pulik richard
sold (taxes)
-25,810
11.03
-2,340
cfo
Apr 24, 2024
fitzgerald meghan
sold (taxes)
-904
10.9
-83.00
-
Apr 24, 2024
fitzgerald meghan
acquired
-
-
1,261
-
Apr 24, 2024
momtazee james c
acquired
-
-
1,490
-
Apr 24, 2024
epperly melissa b,
sold (taxes)
-1,340
10.9
-123
-
Apr 24, 2024
oren ilan
sold (taxes)
-588
10.9
-54.00
-
Apr 24, 2024
epperly melissa b,
acquired
-
-
1,146
-

1–10 of 50

Which funds bought or sold ROIV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.59
588,751
1,632,750
0.21%
May 20, 2024
Virtu Financial LLC
sold off
-100
-136,000
-
-%
May 17, 2024
Artal Group S.A.
sold off
-100
-11,230,000
-
-%
May 17, 2024
Ikarian Capital, LLC
reduced
-33.73
-644,531
1,060,420
0.12%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.25
-381,096
3,061,440
-%
May 16, 2024
JANE STREET GROUP, LLC
added
122
3,855,720
7,391,460
-%
May 15, 2024
VIKING GLOBAL INVESTORS LP
unchanged
-
-47,864,600
731,149,000
2.72%
May 15, 2024
EVENTIDE ASSET MANAGEMENT, LLC
sold off
-100
-12,846,400
-
-%
May 15, 2024
Ionic Capital Management LLC
new
-
527,000
527,000
0.17%
May 15, 2024
PointState Capital LP
new
-
42,650,000
42,650,000
0.73%

1–10 of 42

Are Funds Buying or Selling ROIV?

Are funds buying ROIV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ROIV
No. of Funds

Unveiling Roivant Sciences Ltd.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 02, 2024
sumitomo chemical co., ltd.
0.00%
0
SC 13G/A
Mar 07, 2024
qvt financial lp
8.28%
66,719,779
SC 13G/A
Feb 14, 2024
dexcel pharma technologies ltd.
0.58%
4,684,130
SC 13G/A
Feb 14, 2024
ramaswamy vivek
9.75%
81,454,521
SC 13G/A
Feb 14, 2024
qvt financial lp
13.97%
112,541,536
SC 13G/A
Feb 14, 2024
viking global investors lp
8.6%
69,368,961
SC 13G/A
Feb 13, 2024
sb investment advisers (uk) ltd
9.1%
73,031,667
SC 13G/A
Feb 13, 2024
ramaswamy vivek
9.75%
81,454,521
SC 13G/A
Feb 01, 2024
sumitomo chemical co., ltd.
8.86%
71,251,083
SC 13G/A
Jun 26, 2023
viking global investors lp
9.9%
75,238,700
SC 13G/A

Recent SEC filings of Roivant Sciences Ltd.

View All Filings
Date Filed Form Type Document
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
Apr 30, 2024
4
Insider Trading
Apr 26, 2024
4
Insider Trading
Apr 26, 2024
4
Insider Trading
Apr 26, 2024
4
Insider Trading
Apr 26, 2024
4
Insider Trading
Apr 24, 2024
4
Insider Trading
Apr 24, 2024
4
Insider Trading

Peers (Alternatives to Roivant Sciences Ltd.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

Roivant Sciences Ltd. News

Latest updates
MarketBeat2 hours ago

Roivant Sciences Ltd. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Revenue0.1%37,140,00037,101,00021,624,00027,376,00022,837,75018,299,50013,761,2509,223,00024,341,00013,987,0007,735,00015,146,0005,750,0001,323,000--
Operating Expenses3.5%324,667,000313,555,000298,037,000261,542,000395,129,000293,299,000286,628,000276,026,000270,364,000698,416,000162,122,000555,980,000264,820,000157,864,000116,029,000-
  S&GA Expenses20.0%197,282,000164,355,000156,190,000125,510,000168,261,000157,663,000149,072,000138,973,000115,530,000437,776,00082,754,0003,934,45861,875,00059,740,00057,115,000-
  R&D Expenses-6.3%123,717,000131,984,000125,133,000131,857,000125,533,000131,995,000135,830,000135,077,000137,345,000132,098,00078,515,000-121,778,000202,261,00097,409,00058,734,000-
EBITDA Margin411.1%35.09-11.28-14.65-19.22-1.52-2.08-3.54-16.47--------
Interest Expenses2.1%9,444,0009,247,0008,912,0008,575,0008,446,0008,335,0002,612,000---------
Income Taxes583.3%25,672,0003,757,0001,752,000-3,793,0002,819,0002,165,0003,999,000-163,00038,000401,00093,00019,504-224,000711,0001,221,000-
Earnings Before Taxes1657.4%5,098,337,000-327,361,000-326,093,000-179,216,000-382,077,000-313,756,000-349,785,000-291,476,000-306,047,000-225,239,000-100,985,00019,038,604-275,821,000-52,787,000-6,756,000-
EBT Margin392.3%34.61-11.84-15.28-19.99-1.53-2.10-3.57-16.71-10.02-13.68-13.71-13.29-16.13-12.26-9.89-8.29
Net Income1639.1%5,096,184,000-331,118,000-327,845,000-10,464,000-352,014,000-315,921,000-353,784,000-252,035,000-284,536,000-225,640,000-101,078,00019,019,100-261,029,000-53,498,000-7,977,000-
Net Income Margin460.8%35.92-9.96-12.65-16.65-1.43-1.97-3.40-15.61-9.68-13.34-13.24-12.7534.5326.2521.1717.74
Free Cashflow-7.2%-210,807,000-196,702,000-250,335,000-180,710,000-223,101,000-192,731,000-259,541,000-153,732,000-274,567,000-123,357,000-143,509,000-4,327,983-236,966,000-99,348,000-111,473,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q1
Assets254.0%7,3132,0662,1372,3902,2032,2162,6002,5852,7993,1032,4552,5904132,477
  Current Assets338.7%6,8071,5521,5611,7991,6461,7152,0392,1472,2882,5562,0582,1872.002,219
    Cash Equivalents373.7%6,6711,4081,4341,6771,5411,6131,9562,0742,2262,5092,0082,1422,1532,269
  Net PPE-10.7%22.0024.0036.0039.0037.0039.0032.0026.0022.0017.0016.0015.00-9.00
Liabilities-1.6%72874080378277670182352453065247552864.00368
  Current Liabilities-7.8%2452662452722442313291841613032092191.0092.00
  Short Term Borrowings-------33.00-------
  Long Term Debt3.6%403389385376375376384210172168155150-89.00
    LT Debt, Current-6.7%46.0049.0044.0041.0038.0036.00--------
    LT Debt, Non Current--------210204200186170-109
Shareholder's Equity359.4%6,0901,3261,3341,1581,4271,5141,7552,0392,2472,4281,9572,0402,1712,086
  Retained Earnings116.6%727-4,368-4,100-3,772-3,700-3,387-3,095-2,763-2,493-2,200-2,000-1,918-10.77-1,109
  Additional Paid-In Capital1.3%5,3905,3214,9824,9334,6954,5394,4754,4224,3604,2463,8253,81516.003,144
Shares Outstanding0.5%805801767760713698696695687650650652630629
Minority Interest31.2%495377423450472354371382382390234242-54.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Cashflow From Operations-7.1%-210,452-196,427-249,932-179,088-222,593-189,630-252,082-147,469-268,494-120,596-141,170-237-236,859-98,045-111,167-
  Share Based Compensation10.2%54,32549,31849,26025,27757,73161,97972,79477,15971,216397,31219,26939,44217,32413,91414,278-
Cashflow From Investing14456.4%5,233,041-36,451105113,553-3,511-146,852-7,459-5,702-6,073317,409-2,339200,284-107-1,864-25,641-
Cashflow From Financing13.8%236,639207,8727,477210,332154,495-7,341141,9761,070-8,422303,93410,2105.00464175,956181,130-
  Buy Backs-------8,3298,329--2,247----113-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ROIV Income Statement

2023-12-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Revenues:    
Revenue, net$ 37,140$ 17,052$ 95,865$ 33,904
Operating expenses:    
Cost of revenues3,6683,58611,1488,953
Research and development (includes $7,475 and $6,888 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $24,305 and $26,548 for the nine months ended December 31, 2023 and 2022, respectively)123,717125,533380,834393,358
Acquired in-process research and development097,74926,45097,749
Selling, general and administrative (includes $46,944 and $50,741 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $128,445 and $165,771 for the nine months ended December 31, 2023 and 2022, respectively)197,282168,261517,827474,996
Total operating expenses324,667395,129936,259975,056
Gain on sale of Telavant net assets5,348,41005,348,4100
Income (loss) from operations5,060,883(378,077)4,508,016(941,152)
Change in fair value of investments10,467(25,948)63,88053,277
Change in fair value of debt and liability instruments9,33162,36085,37690,032
Gain on deconsolidation of subsidiaries0(12,514)(17,354)(29,276)
Interest income(31,953)(10,249)(62,967)(17,900)
Interest expense9,4448,44627,60319,393
Other income, net(34,743)(18,095)(33,405)(11,060)
Net income (loss) before income taxes5,098,337(382,077)4,444,883(1,045,618)
Income tax expense25,6722,81931,1818,983
Net income (loss)5,072,665(384,896)4,413,702(1,054,601)
Net loss attributable to noncontrolling interests(23,519)(32,882)(86,339)(79,188)
Net income (loss) attributable to Roivant Sciences Ltd.$ 5,096,184$ (352,014)$ 4,500,041$ (975,413)
Net income (loss) per common share:    
Net income (loss) per common share - basic (in dollars per share)$ 6.37$ (0.49)$ 5.79$ (1.39)
Net income (loss) per common share - diluted (in dollars per share)$ 6.03$ (0.49)$ 5.46$ (1.39)
Weighted average shares outstanding:    
Weighted average shares outstanding, basic (in shares)800,587,716713,319,399776,759,728703,054,773
Weighted average shares outstanding, diluted (in shares)844,461,685713,319,399824,310,013703,054,773
Product Revenue, Net [Member]    
Revenues:    
Revenue, net$ 20,666$ 9,244$ 55,749$ 14,354
License, Milestone and Other Revenue [Member]    
Revenues:    
Revenue, net$ 16,474$ 7,808$ 40,116$ 19,550

ROIV Balance Sheet

2023-12-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Mar. 31, 2023
Current assets:  
Cash and cash equivalents$ 6,670,810$ 1,676,813
Other current assets135,923121,774
Total current assets6,806,7331,798,587
Property and equipment, net21,85739,086
Operating lease right-of-use assets46,89853,251
Investments measured at fair value239,927304,317
Intangible assets, net150,415144,881
Other assets46,84949,482
Total assets7,312,6792,389,604
Current liabilities:  
Accounts payable35,22637,830
Accrued expenses122,148167,129
Operating lease liabilities10,47711,693
Current portion of long-term debt (includes $26,950 and $26,940 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)45,70640,720
Other current liabilities31,34215,076
Total current liabilities244,899272,448
Liability instruments measured at fair value28,37463,546
Operating lease liabilities, noncurrent47,05953,476
Long-term debt, net of current portion (includes $194,560 and $180,700 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively)403,337375,515
Other liabilities4,42817,032
Total liabilities728,097782,017
Commitments and contingencies (Note 11)
Shareholders' equity:  
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 804,890,910 and 760,143,393 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively00
Additional paid-in capital5,390,2604,933,137
Retained earnings / (accumulated deficit)727,287(3,772,754)
Accumulated other comprehensive loss(27,784)(2,617)
Shareholders' equity attributable to Roivant Sciences Ltd.6,089,7631,157,766
Noncontrolling interests494,819449,821
Total shareholders' equity6,584,5821,607,587
Total liabilities and shareholders' equity$ 7,312,679$ 2,389,604
ROIV
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
 CEO
 WEBSITEhttps://roivant.com
 INDUSTRYBiotechnology
 EMPLOYEES904

Roivant Sciences Ltd. Frequently Asked Questions


What is the ticker symbol for Roivant Sciences Ltd.? What does ROIV stand for in stocks?

ROIV is the stock ticker symbol of Roivant Sciences Ltd.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Roivant Sciences Ltd. (ROIV)?

As of Wed May 22 2024, market cap of Roivant Sciences Ltd. is 9.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ROIV stock?

You can check ROIV's fair value in chart for subscribers.

What is the fair value of ROIV stock?

You can check ROIV's fair value in chart for subscribers. The fair value of Roivant Sciences Ltd. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Roivant Sciences Ltd. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ROIV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Roivant Sciences Ltd. a good stock to buy?

The fair value guage provides a quick view whether ROIV is over valued or under valued. Whether Roivant Sciences Ltd. is cheap or expensive depends on the assumptions which impact Roivant Sciences Ltd.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ROIV.

What is Roivant Sciences Ltd.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, ROIV's PE ratio (Price to Earnings) is 2.06 and Price to Sales (PS) ratio is 73.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ROIV PE ratio will change depending on the future growth rate expectations of investors.